发布求助
文献互助 智能选刊 最新文献

Advanced Therapeutics最新文献

筛选
英文 中文
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2026-02-22
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 2","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148118031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-Acting Hydrogel-Based Depot Formulations of Tirzepatide and Semaglutide for the Management of Type 2 Diabetes and Weight 替西帕肽和西马鲁肽的长效水凝胶储备制剂用于治疗2型糖尿病和体重
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2026-02-22 DOI: 10.1002/adtp.202500329
Andrea I. d'Aquino, Changxin Dong, Leslee T. Nguyen, Jerry Yan, Carolyn K. Jons, Olivia M. Saouaf, Ye Eun Song, Noah Eckman, Sara Kapasi, Christian M. Williams, Vannessa Doulames, Samya Sen, Manoj K. Manna, Alakesh Alakesh, Katie Lu, Ian Hall, Eric A. Appel
{"title":"Long-Acting Hydrogel-Based Depot Formulations of Tirzepatide and Semaglutide for the Management of Type 2 Diabetes and Weight","authors":"Andrea I. d'Aquino,&nbsp;Changxin Dong,&nbsp;Leslee T. Nguyen,&nbsp;Jerry Yan,&nbsp;Carolyn K. Jons,&nbsp;Olivia M. Saouaf,&nbsp;Ye Eun Song,&nbsp;Noah Eckman,&nbsp;Sara Kapasi,&nbsp;Christian M. Williams,&nbsp;Vannessa Doulames,&nbsp;Samya Sen,&nbsp;Manoj K. Manna,&nbsp;Alakesh Alakesh,&nbsp;Katie Lu,&nbsp;Ian Hall,&nbsp;Eric A. Appel","doi":"10.1002/adtp.202500329","DOIUrl":"10.1002/adtp.202500329","url":null,"abstract":"<div>\u0000 \u0000 <p>Several incretin hormone therapies have been clinically approved and have revolutionized the treatment of diabetes and obesity. Promising therapeutics include semaglutide (Ozempic and Wegovy), a glucagon-like peptide-1 (GLP-1) receptor agonist, and tirzepatide (Mounjaro), a dual agonist for GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. These molecules help regulate blood glucose levels, enhance insulin secretion and sensitivity, and reduce appetite. Currently, these treatments require weekly injections, which can be challenging for patients to adhere to. We previously reported the development of an injectable hydrogel depot technology enabling months-long release of semaglutide (Sema). Here, we further developed this technology for improved prolonged release of both Sema and tirzepatide (TZP). In a type 2 diabetes rat model, we show that a single administration of hydrogel-based formulations of either Sema or TZP maintained relevant drug levels for over 6 weeks. In these studies, single administrations of long-acting hydrogel-based therapies of Sema or TZP were similarly effective at regulating blood glucose and weight compared to daily injections of either Sema or TZP in standard aqueous vehicles. This injectable hydrogel depot is easy to manufactureand exhibits excellent biocompatibility, enabling months-long treatments with the potential to improve the management of diabetes and weight.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 2","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147288486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2026-02-22
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 2","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148118029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2026-02-22
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 2","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148118030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2026-02-22
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 2","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148118032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Silk Fibroin in Medicine: A Review on ISO10993 Biocompatibility, Preclinical Evidence, and Clinical Perspectives 丝素蛋白在医学上的应用：ISO10993生物相容性、临床前证据和临床前景综述
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2026-02-22 DOI: 10.1002/adtp.202500483
Jirasak Jitpibull, Juthamas Ratanavaraporn
{"title":"Silk Fibroin in Medicine: A Review on ISO10993 Biocompatibility, Preclinical Evidence, and Clinical Perspectives","authors":"Jirasak Jitpibull,&nbsp;Juthamas Ratanavaraporn","doi":"10.1002/adtp.202500483","DOIUrl":"10.1002/adtp.202500483","url":null,"abstract":"<div>\u0000 \u0000 <p>Silk fibroin, a natural protein polymer derived from silkworms, has been widely utilized in the development of biomaterials due to its numerous advantageous properties, including versatile processability into various formats, tunable scaffold characteristics, extended biodegradation time, and low immunogenicity in the human body. This review provides a comprehensive overview of the fundamental properties of silk fibroin—such as its thermal, mechanical, optical, and electrical characteristics—offering insights that can guide the tailoring of this material for specific biomedical applications. It also summarizes relevant safety data, including ISO 10993 series evaluations, which confirm the biocompatibility of silk fibroin by demonstrating its low toxicity, blood compatibility, mild inflammatory response, absence of skin sensitization, and lack of systemic toxicity. Furthermore, this review highlights findings from in vivo models across various tissue types, including skin, bone, and nerve, underscoring the high performance of silk fibroin-based materials in tissue repair and regeneration. Clinical trial reports are also discussed, demonstrating the therapeutic effectiveness, safety, and potential of silk fibroin-based materials for tissue repair and reconstruction in different organs, thereby reinforcing their translational promise for real-world medical applications.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 2","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147288478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radioisotope-Labeled Nanomedicines for Cancer Therapy: Recent Advances, Synergistic Strategies, and Future Challenges 放射性同位素标记的纳米药物用于癌症治疗：最新进展，协同策略和未来挑战
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2026-02-16 DOI: 10.1002/adtp.202500401
Zhisheng Luo, Lu Hao, Peng Liu, Shuo Hu
{"title":"Radioisotope-Labeled Nanomedicines for Cancer Therapy: Recent Advances, Synergistic Strategies, and Future Challenges","authors":"Zhisheng Luo,&nbsp;Lu Hao,&nbsp;Peng Liu,&nbsp;Shuo Hu","doi":"10.1002/adtp.202500401","DOIUrl":"10.1002/adtp.202500401","url":null,"abstract":"<div>\u0000 \u0000 <p>Radioisotope therapy (RIT), a form of internal radiotherapy, eliminates tumors at close range through the emission of α particles, β particles, or Auger electrons during radionuclide decay. It has been extensively applied in the treatment of advanced localized cancers. However, the precise delivery of radionuclides to tumor sites is essential to ensure both the safety and efficacy of RIT. Additionally, intrinsic or acquired tumor resistance can significantly compromise therapeutic outcomes. In recent decades, nanocarriers have been widely investigated for radioisotope delivery, enabling the development of diverse radionuclide-labeled nanomaterials and innovative cancer treatment strategies. This review summarizes therapeutic radioisotopes emitting α, β, or Auger particles and highlights various radionuclide-labeled nanomedicines, including inorganic nanoparticles, organic nanoparticles, and metal–organic frameworks (MOFs). We further discuss the integration of RIT with other modalities, such as chemotherapy, immunotherapy, hyperthermia, and photodynamic therapy, using nanomedicines. Finally, we outline the future prospects and challenges associated with the development and clinical translation of radionuclide-labeled nanomedicines.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 2","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146217221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2026-02-16
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 2","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148111447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2026-02-16
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 2","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148112505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Front Cover: Zinc-Based Nanocomposites for Alzheimer's Therapy: Restoring Metal Homeostasis and Inhibiting Neurotoxic Protein Aggregation (Adv. Therap. 2/2026) 封面：锌基纳米复合材料用于阿尔茨海默病治疗：恢复金属稳态和抑制神经毒性蛋白聚集（ad . Therapy . 2/2026）
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2026-02-15 DOI: 10.1002/adtp.70133
Suman Yadav, Sarvesh Kumar Pandey, Shikha Awasthi
{"title":"Front Cover: Zinc-Based Nanocomposites for Alzheimer's Therapy: Restoring Metal Homeostasis and Inhibiting Neurotoxic Protein Aggregation (Adv. Therap. 2/2026)","authors":"Suman Yadav,&nbsp;Sarvesh Kumar Pandey,&nbsp;Shikha Awasthi","doi":"10.1002/adtp.70133","DOIUrl":"10.1002/adtp.70133","url":null,"abstract":"<p>This cover illustrates Zn-based materials, including Zn metal, ZnO nanoparticles, and Zn–polymer composites, as therapeutic platforms for Alzheimer's disease. These systems regulate zinc homeostasis, inhibit amyloid-β aggregation, reduce oxidative stress, and suppress neuroinflammation, promoting neuronal function and brain health. More details can be found in the Research Article by Suman Yadav, Sarvesh Kumar Pandey, and Shikha Awasthi (DOI: 10.1002/adtp.202500576).\u0000\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 2","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://advanced.onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.70133","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146217082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书